Key highlights on Hypothyroidism today
“Genetic Variants: GWAS have identified genetic variants that influence thyroid hormone production, paving the way for personalized med.
Environmental Factors: Endocrine disruptors are recognized as significant contributors to thyroid dysfunction.
Novel Biomarkers: Biomarkers like reverse T3 & deiodinase enzymes are improving diagnostic accuracy.
Therapeutic Approaches: Levothyroxine remains the primary treatment, but new combinations and controlled-release formulations are being explored.
Lifestyle and Nutrition: Diet, exercise, stress management, and complementary medicine are being integrated into treatment plans.
Immunotherapies and Stem Cell Therapy: These emerging therapies are being studied for their potential to improve outcomes in hypothyroidism.
These highlights reflect the current state of research and treatment strategies for hypothyroidism, emphasizing the need for a multidimensional approach to patient care.”
Journal of Chemical Risks-JCHR (Understanding Hypothyroidism: A Clear Look at Current Research and Treatment | Journal of Chemical Health Risks)
Key Highlights on Hyperthyroidism today:
“Approximately 1.2 percent of the United States population has hyperthyroidism.
Women are 2 to 10 times more likely to develop hyperthyroidism than men.
The prevalence of hyperthyroidism is approximately 0.5 percent in the general population for overt cases.
Graves’ disease accounts for 60 to 80 percent of all hyperthyroidism cases.
Toxic multinodular goiter accounts for 15 to 20 percent of hyperthyroidism cases.
Toxic adenoma accounts for approximately 3 to 5 percent of hyperthyroidism cases.
Approximately 25 to 50 percent of people with Graves’ disease will develop thyroid eye disease (ophthalmopathy).
Atrial fibrillation occurs in 10 to 15 percent of patients with hyperthyroidism.
Thyroid storm has a mortality rate of 10 to 30 percent if not treated immediately.
Remission rates for Graves’ disease after 12-18 months of antithyroid drug therapy are about 40 to 50 percent.
Radioactive iodine therapy cures hyperthyroidism in approximately 90 percent of patients with a single dose.
Hypothyroidism develops in more than 80 percent of patients treated with radioactive iodine for Graves’ disease within 10 years.
Overt hyperthyroidism complicates 0.1 to 0.4 percent of all pregnancies.
Subclinical hyperthyroidism is estimated to occur in up to 15 percent of elderly subjects aged 80 and over.
Neonatal Graves’ disease occurs in 1 to 5 percent of infants born to mothers with Graves’ disease.”
GITNUX (Hyperthyroidism Statistics Statistics: Market Data Report 2025)